Recent

% | $
Quotes you view appear here for quick access.

Amgen Inc. Message Board

  • cramerstrophywife cramerstrophywife Feb 8, 2012 9:15 AM Flag

    Briefing.com let's rock AMGN!!!

    8:07AM Amgen announced data for XGEVA to treat men with castration-resistant prostate cancer; data showed that XGEVA significantly reduced the risk for bone metastases or death by 15 percent and increased bone metastasis-free survival (AMGN) 69.18 : The primary analysis of the overall '147 study population showed that XGEVA significantly reduced the risk for bone metastases or death by 15 percent and increased bone metastasis-free survival, or the time a patient went without developing bone metastasis, by a median of 4.2 months. In exploratory analyses of patients with PSA doubling time of 10 months or less, XGEVA prolonged median bone metastasis-free survival time by 6.0 months compared with placebo with a 16 percent reduction in risk. In patients with PSA doubling time of 6 months or less, XGEVA prolonged median bone metastasis-free survival time by 7.2 months compared with placebo with a 23 percent reduction in risk. No new safety risks were identified in the study. Adverse events and serious adverse events were relatively similar between the XGEVA and placebo arms.

 
AMGN
153.19-1.06(-0.69%)9:32 AMEDT